Products
Eculizumab Biosimilar Monoclonal Antibody (Complement C5) for Research
Pre-Made Eculizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.[2][3][4][5] It is given in a clinic by intravenous (IV) infusion.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-164-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Eculizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody |
| INN Name | Eculizumab |
| Target | CO5 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5i5k:HL:XY |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2002 |
| Year Recommended | 2003 |
| Companies | Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc |
| Conditions Approved | Neuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria |
| Conditions Active | Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19 |
| Conditions Discontinued | Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus |
| Development Tech | GS Gene Expression System |
About target - C5
1. Protein Complement C5
2. Gene C5
3. Organism Homo sapiens (Human)
Function
Dipeptidase that hydrolyzes cystinyl-bis-glycine. Does not hydrolyze leukotriene D4 (LTD4) into leukotriene E4 (LTE4).
Catalytic activity
an L-aminoacyl-L-amino acid + H2O = 2 an L-α-amino acid
EC:3.4.13.19
Source: Rhea.
2 H2O + L-cystine-bis-glycine = 2 glycine + L-cystine
Source: Rhea.
Cofactor
Zn2+
Activity regulation
Inhibited by L-penicillamine.
